Prostate cancer is the second leading cause of cancer death in men in the US. The initial treatment of metastatic prostate cancer is androgen deprivation (castration) therapy and this is achieved through either surgical or medical castration, however these therapies are also associated with undesirable side effects including impotence, tumour flare and loss of bone mass. Over time, nearly all patients with metastatic disease become resistant to androgen deprivation, progressing to castration-resistant prostate cancer (CRPC), and at this stage of the disease the prognosis is extremely poor (<50 % survival at two years). Currently there are few treatment options for CRPC. Only four have been found to extend survival and none are curative. Effective treatment of CRPC is a major unmet clinical need, and the identification of alternative therapeutic targets is an active focus of research. In this article we discuss the development of a new agent, Val 201 as a potential future treatment for CRPC. VAL 201 targets the association of androgen receptor with Src, a non-receptor tyrosine kinase signal-transduction protein that is important in tumour cell proliferation, and represents a novel and exciting approach for cancer chemotherapy.
In 2010, prostate cancer was the most commonly found malignant cancer in men, comprising 28 % of all new cancer cases. 1 In the US, it is the second leading cause of cancer death in men, with annual mortality rates of approximately 30,000 deaths per year. 1 Symptoms of the disease include: frequent and/or painful urination; difficulty in starting or stopping urination; changes in sexual function; and weight loss.
Diagnosis of the disease is confirmed by biopsy. Factors that impact a patient's prognosis include the stage of cancer (whether it is localised, locally advanced or metastatic), the Gleason score (a score system based on tumour morphology and histology) and the level of prostatespecific antigen in the blood. In the UK, approximately 20 % of men with primary prostate cancer present with incurable metastatic disease. 2 Prostate cancer metastasises preferentially to bone, 3 and metastatic bone disease is responsible for a significant proportion of morbidity and mortality associated with the advanced stages of this disease. During prostate cancer progression, activation of the androgen receptor (AR) by androgens such as testosterone and dihydrotestosterone stimulates cell proliferation and inhibits apoptosis in prostate cancer cells. The initial treatment of metastatic prostate cancer is androgen deprivation (castration) therapy and this is achieved through either surgical or medical castration. Over time nearly all patients with metastatic disease become resistant to androgen deprivation, progressing to castrationresistant prostate cancer (CRPC) which is usually fatal.
Development of Castration-resistant Prostate Cancer
There are multiple mechanisms that can drive disease progression to CRPC, and most involve the AR pathway. 4 Resistance to castration therapy can be due to altered AR sensitivity, amplification of AR or mutations. Alternative splicing of the AR gene can lead to the expression of ARs lacking the ligand-binding domain and which are constitutively active. Additionally, CRPC can be caused by ectopic androgen synthesis, such as androgen synthesis by the adrenal glands, the tumour itself or increased conversion of extra-gonadal androgens to testosterone. Other mechanisms of progression to CRPC include modulation of AR co-regulators (again leading to increased signalling of the AR pathway) and, lastly, there can be activation of compensatory AR-independent pathways, which lead to cell proliferation and inhibition of apoptosis.
Current Treatments for Castration-resistant Prostate Cancer
Prior to 2010 docetaxel was the only approved agent for CRPC, and currently only three other systemic agents have demonstrated an increase in overall survival in patients with metastatic CRPC.
Mitoxantrone, a type II topoisomerase inhibitor, has not demonstrated a survival improvement but remains a palliative therapeutic option. The majority of the current Src inhibitors in development are either multitargeted (and also inhibit other receptors) or completely inhibit all Src activity, or both. 31 The exception to this is VAL 201, a novel deca-peptide that is currently under development for the treatment of CRPC. VAL 201 specifically targets AR-associated/activated Src, leaving Src activity and DNA synthesis unaffected in AR-negative cells, and is the first example of a specific inhibitor of steroid-receptor-dependent signal transducing activity.
Overview of the Mechanism of Action of VAL 201
In human mammary and prostate cancer cells, steroid hormones or epidermal growth factor (EGF) trigger association of the AR-estradiol VAL 201 -An Inhibitor of Androgen Receptor-associated Src
receptor (ER) complex with Src, which activates Src and affects the G1 to S cell cycle progression (see Figure 1) . 22 
Preclinical Studies
As previously mentioned, VAL 201 has been shown to be highly effective against prostate and breast cancer cell lines and mouse xenografts. 26 The in vitro half-life for VAL 201 in human liver microsomes Figure 2) . 26 The control treatments, vehicle and scrambled peptide, showed no inhibition of xenograft development demonstrating the specific activity of VAL 201. In another study, a reduction of cell proliferation was seen in hormone-responsive and -refractory cells with no overt chronic toxicity effects (see Figure 3) .
As noted earlier, hormone therapies are associated with undesirable side effects including impotence, hot flashes, gynaecomastia, increase in body fat, osteoporosis, decrease in muscle mass, depression and fatigue. 17 These side effects can significantly affect quality of life. The current first-line chemotherapeutic treatment for CRPC is docetaxel which is a cell cycle specific agent, and thus cytotoxic to all dividing cells in the body. Because of this, side effects such as alopecia and neutropenia are common. 32 Owing to the mechanism of action of VAL 201, this peptide is potentially less toxic than other first choice therapeutic options for prostate cancer.
Additionally this peptide is being developed into an oral formation and has a good pharmacokinetic profile in vivo.
To further evaluate VAL 201 as a therapeutic option for the treatment of prostate cancer, the following clinical studies have been proposed.
Firstly, a microdosing study is being considered so that at an early stage of clinical development good human pharmacokinetic data will become available. However, the option to dose pre-prostatectomy patients is being contemplated, and this would give access to biopsy samples for subsequent targeting analysis. The clinical development programme of VAL 201 is currently at the planning stage.
Future Developments
VAL 201 is equally efficacious in androgen-AR and estradiol-ER modulation, and this opens up a range of potential disease targets beyond prostate cancer. There is significant potential for the use of
Prostate Cancer The VAL 201 peptide (S1) clearly inhibits cell proliferation in both systems at 5 nm, whereas the scrambled peptide (Ss) has only a minor effect in the hormone-dependent cells.
